Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.
Depression in patients with mastocytosis is often reported but its prevalence and characteristics are not precisely described. In addition, the impact of therapies targeting mast cells proliferation, differentiation and degranulation on psychic symptoms of depression have never been investigated. Ou...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2011
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/f04c1496e096403089243bc06b6ecabc |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:f04c1496e096403089243bc06b6ecabc |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:f04c1496e096403089243bc06b6ecabc2021-11-18T07:35:57ZDepression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.1932-620310.1371/journal.pone.0026375https://doaj.org/article/f04c1496e096403089243bc06b6ecabc2011-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22031830/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Depression in patients with mastocytosis is often reported but its prevalence and characteristics are not precisely described. In addition, the impact of therapies targeting mast cells proliferation, differentiation and degranulation on psychic symptoms of depression have never been investigated. Our objective was to determine the prevalence and to describe features of depression in a large cohort of mastocytosis patients (n = 288) and to investigate the therapeutic impact of the protein kinase inhibitor masitinib in depression symptoms. The description of depression was based on the analysis of a database with Hamilton scores using Principal Component Analysis (PCA). Efficacy of masitinib therapy was evaluated using non parametric Wilcoxon test for paired data within a three months period (n = 35). Our results show that patients with indolent mastocytosis present an elevated prevalence of depression (64%). Depression was moderate in 56% but severe in 8% of cases. Core symptoms (such as psychic anxiety, depressed mood, work and interests) characterized depression in mastocytosis patients. Masitinib therapy was associated with significant improvement (67% of the cases) of overall depression, with 75% of recovery cases. Global Quality of Life slightly improved after masitinib therapy and did not predicted depression improvement. In conclusion, depression is very frequent in mastocytosis patients and masitinib therapy is associated with the reduction its psychic experiences. We conclude that depression in mastocytosis may originate from processes related to mast cells activation. Masitinib could therefore be a useful treatment for mastocytosis patients with depression and anxiety symptoms.Daniela Silva MouraSerge SultanSophie Georgin-LavialleNathalie PilletFrançois MontestrucPaul GinesteStéphane BareteGandhi DamajAlain MoussyOlivier LortholaryOlivier HerminePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 10, p e26375 (2011) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Daniela Silva Moura Serge Sultan Sophie Georgin-Lavialle Nathalie Pillet François Montestruc Paul Gineste Stéphane Barete Gandhi Damaj Alain Moussy Olivier Lortholary Olivier Hermine Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. |
| description |
Depression in patients with mastocytosis is often reported but its prevalence and characteristics are not precisely described. In addition, the impact of therapies targeting mast cells proliferation, differentiation and degranulation on psychic symptoms of depression have never been investigated. Our objective was to determine the prevalence and to describe features of depression in a large cohort of mastocytosis patients (n = 288) and to investigate the therapeutic impact of the protein kinase inhibitor masitinib in depression symptoms. The description of depression was based on the analysis of a database with Hamilton scores using Principal Component Analysis (PCA). Efficacy of masitinib therapy was evaluated using non parametric Wilcoxon test for paired data within a three months period (n = 35). Our results show that patients with indolent mastocytosis present an elevated prevalence of depression (64%). Depression was moderate in 56% but severe in 8% of cases. Core symptoms (such as psychic anxiety, depressed mood, work and interests) characterized depression in mastocytosis patients. Masitinib therapy was associated with significant improvement (67% of the cases) of overall depression, with 75% of recovery cases. Global Quality of Life slightly improved after masitinib therapy and did not predicted depression improvement. In conclusion, depression is very frequent in mastocytosis patients and masitinib therapy is associated with the reduction its psychic experiences. We conclude that depression in mastocytosis may originate from processes related to mast cells activation. Masitinib could therefore be a useful treatment for mastocytosis patients with depression and anxiety symptoms. |
| format |
article |
| author |
Daniela Silva Moura Serge Sultan Sophie Georgin-Lavialle Nathalie Pillet François Montestruc Paul Gineste Stéphane Barete Gandhi Damaj Alain Moussy Olivier Lortholary Olivier Hermine |
| author_facet |
Daniela Silva Moura Serge Sultan Sophie Georgin-Lavialle Nathalie Pillet François Montestruc Paul Gineste Stéphane Barete Gandhi Damaj Alain Moussy Olivier Lortholary Olivier Hermine |
| author_sort |
Daniela Silva Moura |
| title |
Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. |
| title_short |
Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. |
| title_full |
Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. |
| title_fullStr |
Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. |
| title_full_unstemmed |
Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. |
| title_sort |
depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2011 |
| url |
https://doaj.org/article/f04c1496e096403089243bc06b6ecabc |
| work_keys_str_mv |
AT danielasilvamoura depressioninpatientswithmastocytosisprevalencefeaturesandeffectsofmasitinibtherapy AT sergesultan depressioninpatientswithmastocytosisprevalencefeaturesandeffectsofmasitinibtherapy AT sophiegeorginlavialle depressioninpatientswithmastocytosisprevalencefeaturesandeffectsofmasitinibtherapy AT nathaliepillet depressioninpatientswithmastocytosisprevalencefeaturesandeffectsofmasitinibtherapy AT francoismontestruc depressioninpatientswithmastocytosisprevalencefeaturesandeffectsofmasitinibtherapy AT paulgineste depressioninpatientswithmastocytosisprevalencefeaturesandeffectsofmasitinibtherapy AT stephanebarete depressioninpatientswithmastocytosisprevalencefeaturesandeffectsofmasitinibtherapy AT gandhidamaj depressioninpatientswithmastocytosisprevalencefeaturesandeffectsofmasitinibtherapy AT alainmoussy depressioninpatientswithmastocytosisprevalencefeaturesandeffectsofmasitinibtherapy AT olivierlortholary depressioninpatientswithmastocytosisprevalencefeaturesandeffectsofmasitinibtherapy AT olivierhermine depressioninpatientswithmastocytosisprevalencefeaturesandeffectsofmasitinibtherapy |
| _version_ |
1718423259928592384 |